This research used detailed cell analysis to look at patients receiving daratumumab-bortezomib-dexamethasone for primary light-chain amyloidosis. The team compared those who responded well to treatment against those who had suboptimal responses. The goal was to understand why some patients do not respond as expected to this drug combination.
Patients with weaker responses showed lower activity in genes related to protein translation and cell adhesion before treatment started. During treatment, their cells showed signs of stress and increased activity in certain immune pathways. Additionally, their immune cells, such as myeloid cells and natural killer cells, appeared to function less effectively compared to those with good responses.
These results suggest that specific biological differences might be linked to treatment response. However, because the study included only 30 patients and was observational, it cannot prove that these changes cause resistance. The findings are currently descriptive and intended to generate new ideas for future research. Readers should not view these results as proof of a new treatment failure or a definitive cause for poor outcomes.